UK BIOBANK LIMITED
To provide a major genetic resource to assist scientists with research into a variety of diseases and illnesses.
Objects
THE OBJECTS FOR WHICH THE COMPANY IS ESTABLISHED ARE TO PROTECT, PRESERVE AND ADVANCE ALL OR ANY ASPECTS OF THE HEALTH AND WELFARE OF HUMAN BEINGS AND TO ADVANCE AND PROMOTE KNOWLEDGE AND EDUCATION BY ENGAGING IN, ENCOURAGING AND SUPPORTING: 1) INVESTIGATIONS INTO THE SEPARATE AND COMBINED EFFECTS OF GENETIC, ENVIRONMENTAL (INCLUDING LIFESTYLE, PHYSIOLOGICAL AND ENVIRONMENTAL EXPOSURES) AND OTHER FACTORS ON HUMAN HEALTH AND WELFARE AND ON THE RISK AND CAUSATION OF DISEASES IN THE HUMAN POPULATION; (2) THE ESTABLISHMENT, HOLDING, OPERATION, MANAGEMENT, PROMOTION, SUPPORT, EXPANSION, IMPROVEMENT AND SAFEGUARDING OF A COLLECTION OF BIOMEDICAL, BIOCHEMICAL, EPIDEMIOLOGICAL, GENETIC AND OTHER DATA AND BLOOD AND OTHER BIOLOGICAL AND BIOCHEMICAL SAMPLES OBTAINED AND DEVELOPED THROUGH, FOR THE PURPOSE OF AND/OR IN CONNECTION WITH SOME OR ALL OF THE INVESTIGATIONS REFERRED TO IN PARAGRAPH (1) AND PERTAINING TO A COHORT OF HUMAN PARTICIPANTS ("DATA AND SAMPLES"), FOR USE IN A RESEARCH, KNOWLEDGE AND INFORMATION RESOURCE PROVISIONALLY KNOWN AS THE UK BIOBANK ("THE RESOURCE");(3) RESEARCH INTO BIOLOGICAL AND MEDICAL SCIENCES AND OTHER DISCIPLINES WHICH MAY CONTRIBUTE TO THE IMPROVEMENT OF HUMAN HEALTH AND WELFARE("THE BIOSCIENCES"); (4) THE DISCOVERY, INVENTION, IMPROVEMENT, DEVELOPMENT AND APPLICATION OF TREATMENTS, CURES, DIAGNOSTICS AND OTHER MEDICINAL AGENTS, METHODS AND PROCESSES THAT MAY IN ANY WAY RELIEVE ILLNESS, DISEASE, DISABILITY OR DISORDERS OF WHATEVER NATURE IN HUMAN BEINGS; AND (5) THE STUDY AND UNDERSTANDING OF ANY OF THE BIOSCIENCES.
Financial health, per its FY2025 accounts
The accounts state that total income decreased by 10% to £68.9m, while charitable expenditure excluding pension releases increased by 25% to £47.3m. Free reserves increased to £7.9m, which the trustees consider to be within their stated policy target range of £5m to £10m. The directors confirm that sufficient funding is available for the charity to continue operating for the foreseeable future.
What the accounts disclose
“Infrastructure Project Funding 24.9”
“The trustees consider an appropriate level of reserves to hold in respect of these risks is between £5m and £10m, which is broadly equivalent to between 2.5 and 5 months of core running costs”
Policies the charity declares
- Bullying and harassment policy and procedures
- Complaints handling
- Complaints policy and procedures
- Conflicting interests
- Financial reserves policy and procedures
- Internal charity financial controls policy and procedures
- Internal risk management policy and procedures
- Investing charity funds policy and procedures
- Investment
- Paying staff
- Risk management
- Safeguarding policy and procedures
- Serious incident reporting policy and procedures
- Social media policy and procedures
- Trustee conflicts of interest policy and procedures
- Trustee expenses policy and procedures
From the charity’s annual return (Part A, self-declared)
Self-declared on the annual return for the financial year ending 30/09/2025
- Government income: £33,144,337 — grants £33,144,337 (7); 48% of the £68,919,118 total gross income on the same return
- Employees paid over £60,000: 56 (£60,001–£70,000: 22; £70,001–£80,000: 14; £80,001–£90,000: 7; £90,001–£100,000: 6; £120,001–£130,000: 2; £140,001–£150,000: 1; £150,001–£200,000: 2; £200,001–£250,000: 1; £250,001–£300,000: 1)
Self-declared on the annual return for the financial year ending 30/09/2024
- Government income: £44,243,366 — grants £44,243,366 (8); 58% of the £76,327,574 total gross income on the same return
- Employees paid over £60,000: 43 (£60,001–£70,000: 19; £70,001–£80,000: 8; £80,001–£90,000: 4; £90,001–£100,000: 3; £100,001–£110,000: 2; £110,001–£120,000: 1; £130,001–£140,000: 1; £140,001–£150,000: 1; £150,001–£200,000: 3; £200,001–£250,000: 1)
Self-declared on the annual return for the financial year ending 30/09/2023
- Government income: £13,384,924 — grants £13,384,924 (10); 39% of the £34,535,326 total gross income on the same return
- Employees paid over £60,000: 28 (£60,001–£70,000: 13; £70,001–£80,000: 4; £80,001–£90,000: 3; £90,001–£100,000: 2; £110,001–£120,000: 1; £150,001–£200,000: 5)
Corporate structure
- Registered company of the charity Companies House 04978912
Company officers (Companies House)
- WOOD, Anthony, Dr on trustee list
- WILLIAMS, Ceri Louise, Dr on trustee list
- MILLS, Melinda Catherine, Professor on trustee list
- TAYLOR, Bernard John on trustee list
- PERRIN, Nicola on trustee list
- FERGUSON, Michael Anthony John, Professor Sir on trustee list
- ROTHWELL, Nancy, Dame on trustee list
- KAKKAR, Ajay Kumar, Professor Lord on trustee list
- MARKHAM, Alexander Fred, Sir not on trustee list
- SELLORS, Jonathan Michael Holmes
Property (HM Land Registry)
Structured financials (annual return, FY ending 30/09/2025)
Trustees
- Lord Ajay Kumar Kakkarchair
- Bernard Taylor
- Dr Anthony Wood
- Dr Ceri Louise Williams
- Nicola Perrin
- PROFESSOR SIR ALEX MARKHAM
- Professor Dame Nancy Jane Rothwell
- Professor Melinda Catherine Mills
- Professor Rachel McKendry
- Professor Sir Michael Ferguson
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 30/09/2025 | £68.9m | £47.3m |
| 30/09/2024 | £76.3m | £30.6m |
| 30/09/2023 | £34.5m | £32.1m |
| 30/09/2022 | £40.6m | £38.9m |
| 30/09/2021 | £62.7m | £63.6m |
Common questions
Is UK BIOBANK LIMITED financially healthy?
Per its FY2025 accounts: The accounts state that total income decreased by 10% to £68.9m, while charitable expenditure excluding pension releases increased by 25% to £47.3m. Free reserves increased to £7.9m, which the trustees consider to be within their stated policy target range of £5m to £10m. The directors confirm that sufficient funding is available for the charity to continue operating for the foreseeable future. Its FY2025 accounts were audited by BDO LLP.
Who funds UK BIOBANK LIMITED?
Funders whose own accounts filings name UK BIOBANK LIMITED as a grant recipient include WELLCOME TRUST.
Known funders
| Funder | Year | Amount | Purpose (as stated by the funder) |
|---|---|---|---|
| WELLCOME TRUST | FY2024 | £30.1m | Discovery Research |
Funders of similar charities
| Funder | Similar charities funded | Amount to them |
|---|---|---|
| THE BARBOUR FOUNDATION | 3 | £8k |
| THE JENOUR FOUNDATION | 2 | £11k |
| THE CHARLES AND ELSIE SYKES TRUST | 2 | £10k |
| THE FRANK LITCHFIELD GENERAL CHARITABLE TRUST | 2 | £7k |
| THE WILLIE AND MABEL MORRIS CHARITABLE TRUST | 2 | £6k |
| THE OAKDALE TRUST | 2 | £6k |
| JOHN SWIRE 1989 CHARITABLE TRUST | 2 | £4k |
| SSP FOUNDATION | 2 | £3k |
Charities like this
- GENOME RESEARCH LIMITED
- MEDICAL RESEARCH FOUNDATION
- Blood Cancer UK Research
- UKGBC
- BREAST CANCER UK LIMITED
- EARLHAM INSTITUTE
Side by side with its peers
| Charity | Income | Top pay band | Staff >£60k | Reserves vs policy | Fundraising cost | Going concern |
|---|---|---|---|---|---|---|
| UK BIOBANK LIMITED | £68.9m | — | — | within | — | no doubt |
| GENOME RESEARCH LIMITED | £180.3m | £290,000 to £299,999 | — | unclear | — | no doubt |
| MEDICAL RESEARCH FOUNDATION | £3.7m | — | — | unclear | — | no doubt |
| Blood Cancer UK Research | £21.1m | — | — | unclear | — | no doubt |
| UKGBC | £3.1m | — | — | unclear | — | no doubt |
| BREAST CANCER UK LIMITED | £2.1m | — | 0 | above | 17.7% | no doubt |